# A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS

> **NCT05456269** · PHASE1 · WITHDRAWN · sponsor: **Racura Oncology Ltd**

## Conditions studied

- Acute Myeloid Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Higher Risk Myelodysplastic Syndrome
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** Bisantrene Dihydrochloride (high dose)
- **DRUG:** Bisantrene Dihydrochloride (low dose)
- **DRUG:** Cytarabine Hydrochloride
- **DRUG:** Decitabine and cedazuridine

## Key facts

- **NCT ID:** NCT05456269
- **Lead sponsor:** Racura Oncology Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-07-29
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-08-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** commercial reason
- **Last updated:** 2023-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05456269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05456269, "A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05456269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*